Efficacy and Tolerability of Erenumab in the Management of Persistent Redness and Flushing in Rosacea
Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
An exploratory open-label study of rosacea patients to study the efficacy and tolerability of
erenumab in the prophylactic treatment of persistent redness and flushing attributed to
rosacea. Approximately 30 subjects will be included in the study and receive erenumab 140 mg
for three months. The study will begin June 2020 and is expected to last nine months.
Phase:
Phase 2
Details
Lead Sponsor:
Messoud Ashina
Collaborators:
Danish Headache Center Herlev and Gentofte Hospital Novartis Pharmaceuticals